Drug development in higher-risk myelodysplastic syndromes

被引：0
|
作者：
Sangeetha Venugopal [1 ]
Mikkael A. Sekeres [1 ]
机构：
[1] University of Miami,Division of Hematology, Sylvester Comprehensive Cancer Center
来源：
Blood Cancer Journal | / 14卷 / 1期
关键词：
D O I：
10.1038/s41408-024-01171-y
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [21] Azacitidine A Review of its Use in Higher-Risk Myelodysplastic Syndromes/Acute Myeloid Leukaemia
    Keating, Gillian M.
    DRUGS, 2009, 69 (17) : 2501 - 2518
  • [22] Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    O'Keefe, Christine
    List, Alan F.
    Paulic, Katarina
    Afable, Manuel, II
    Englehaupt, Ricki
    Maciejewski, Jaroslaw P.
    AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (01) : 102 - 103
  • [23] Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.
    Zeidan, Amer Methqal
    Joshi, Namita
    Kale, Hrishikesh
    Wang, Wei-Jhih
    Corman, Shelby
    Hill, Kala
    Salimi, Tehseen
    Epstein, Robert S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] AzacitidineA Review of its Use in Higher-Risk Myelodysplastic Syndromes/Acute Myeloid Leukaemia
    Gillian M. Keating
    Drugs, 2009, 69 : 2501 - 2518
  • [25] Gene methylation and cytogenetic abnormalities in patients (pts) with higher-risk myelodysplastic syndromes.
    Mufti, G. J.
    Herman, J. G.
    Gore, S.
    Seymour, J. F.
    Santini, V.
    Hagemeijer, A. M.
    Skikne, B.
    MacBeth, K. J.
    Lucy, L. M.
    Beach, C. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Tiu, Ramon V.
    Komrokji, Rami
    Lancet, Jeffrey
    Advani, Anjali S.
    Afable, Manuel
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Tabarroki, Ali
    Visconte, Valeria
    Makishima, Hideki
    Jerez, Andres
    Paquette, Ronald
    List, Alan F.
    Maciejewski, Jaroslaw P.
    BLOOD, 2012, 120 (25) : 4945 - 4951
  • [27] Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes
    Chou, Wen-Chien
    Yeh, Su-Peng
    Hsiao, Liang-Tsai
    Lin, Sheng-Fung
    Chen, Yeu-Chin
    Chen, Tsai-Yun
    Laille, Eric
    Galettis, Anoula
    Dong, Qian
    Songer, Steve
    Beach, C. L.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (05) : E430 - E439
  • [28] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply
    Bernal, T.
    Martinez-Camblor, P.
    Sanchez-Garcia, J.
    Sanz, G.
    LEUKEMIA, 2016, 30 (03) : 740 - 741
  • [29] Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
    Zeidan, A. M.
    Sekeres, M. A.
    Garcia-Manero, G.
    Steensma, D. P.
    Zell, K.
    Barnard, J.
    Ali, N. A.
    Zimmerman, C.
    Roboz, G.
    DeZern, A.
    Nazha, A.
    Jabbour, E.
    Kantarjian, H.
    Gore, S. D.
    Maciejewski, J. P.
    List, A.
    Komrokji, R.
    LEUKEMIA, 2016, 30 (03) : 649 - 657
  • [30] Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides
    A M Zeidan
    M A Sekeres
    G Garcia-Manero
    D P Steensma
    K Zell
    J Barnard
    N A Ali
    C Zimmerman
    G Roboz
    A DeZern
    A Nazha
    E Jabbour
    H Kantarjian
    S D Gore
    J P Maciejewski
    A List
    R Komrokji
    Leukemia, 2016, 30 : 649 - 657
12345